Latest Healthcare News

BlinkLab Limited has responded to an ASX query regarding recent unusual trading activity, confirming no undisclosed material information exists and highlighting pending ADHD diagnostic results expected later this year.

Cardiex Limited has successfully raised $4.1 million through a fully underwritten entitlement offer, bringing total funds raised to $6.5 million including a recent institutional placement. The offer saw strong participation from directors and key shareholders, with new shares set to be issued imminently.

Adherium Limited has announced an accelerated non-renounceable entitlement offer to raise approximately A$4 million, issuing new shares and options to fund expansion and product development. The offer includes a Top-Up Facility and is partially underwritten, signaling a strategic push to scale its respiratory monitoring technology.

Adherium Limited is raising up to $4 million through a partially underwritten entitlement offer to expand its US digital health platform and recruit key personnel. The capital raise supports scaling patient onboarding and advancing its FDA-cleared smart inhaler technology.

Radiopharm Theranostics has inked a clinical supply agreement with Cyclotek to support its Phase 1 trial of RAD 402, a novel radiotherapeutic targeting prostate cancer, set to commence in Australia in late 2025.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Cogstate Ltd has upgraded its FY25 financial guidance, projecting a 20-24% revenue increase and nearly doubling profit before tax compared to last year.

Amplia Therapeutics has secured US ethics approval to launch a Phase 2 trial combining its drug narmafotinib with FOLFIRINOX chemotherapy for advanced pancreatic cancer, marking a key step in its clinical development.

INOVIQ Limited has responded to ASX queries defending its announcement that its new CAR-NK-EV treatment killed 88% of breast and lung cancer cells in vitro, confirming compliance with disclosure rules and providing detailed study data.

Microba Life Sciences Limited has had its trading suspension lifted following a capital raising announcement, signaling renewed market activity for the healthcare company.

Microba Life Sciences announces a $12.5 million equity raise, including a strategic $8.3 million investment from Sonic Healthcare, aiming to fuel growth in the UK and achieve regional break-even by FY26.

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.